Skip to main content

. 1986;22(Suppl 1):71S–75S. doi: 10.1111/j.1365-2125.1986.tb02986.x

Post-marketing surveillance in the UK (1984)

PMCID: PMC1401005 PMID: 3567035

71S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Colin-Jones D. G., Langman M. J., Lawson D. H., Vessey M. P. Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study. Br Med J (Clin Res Ed) 1982 Nov 6;285(6351):1311–1313. doi: 10.1136/bmj.285.6351.1311. [DOI] [PubMed] [Google Scholar]
Colin-Jones D. G., Langman M. J., Lawson D. H., Vessey M. P. Postmarketing surveillance of the safety of cimetidine: 12 month mortality report. Br Med J (Clin Res Ed) 1983 May 28;286(6379):1713–1716. doi: 10.1136/bmj.286.6379.1713. [DOI] [PMC free article] [PubMed] [Google Scholar]
Crombie I. K. The role of record linkage in post-marketing drug surveillance. Br J Clin Pharmacol. 1986;22 (Suppl 1):77S–82S. doi: 10.1111/j.1365-2125.1986.tb02987.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Dollery C. T., Rawlins M. D. Monitoring adverse reactions to drugs. Br Med J. 1977 Jan 8;1(6053):96–97. doi: 10.1136/bmj.1.6053.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
Feinstein A. R., Horwitz R. I. Double standards, scientific methods, and epidemiologic research. N Engl J Med. 1982 Dec 23;307(26):1611–1617. doi: 10.1056/NEJM198212233072604. [DOI] [PubMed] [Google Scholar]
Harcus A. W., Ward A. E., Smith D. W. Methodology of monitored release of a new preparation: buprenorphine. Br Med J. 1979 Jul 21;2(6183):163–165. doi: 10.1136/bmj.2.6183.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
Lawson D. H., Henry D. A. Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"? Br Med J. 1977 Mar 12;1(6062):691–692. doi: 10.1136/bmj.1.6062.691. [DOI] [PMC free article] [PubMed] [Google Scholar]
Maclay W. P., Crowder D., Spiro S., Turner P. Postmarketing surveillance: practical experience with ketotifen. Br Med J (Clin Res Ed) 1984 Mar 24;288(6421):911–914. doi: 10.1136/bmj.288.6421.911. [DOI] [PMC free article] [PubMed] [Google Scholar]
Rawlins M. D. Postmarketing surveillance of adverse reactions to drugs. Br Med J (Clin Res Ed) 1984 Mar 24;288(6421):879–880. doi: 10.1136/bmj.288.6421.879. [DOI] [PMC free article] [PubMed] [Google Scholar]
Wilson A. B. Post-marketing surveillance of adverse reactions to new medicines. Br Med J. 1977 Oct 15;2(6093):1001–1003. doi: 10.1136/bmj.2.6093.1001. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES